mTOR Inhibitor Response Markers
mTOR Inhibitor sensitivity: PIK3CA mutation
Nicolantonio, F.D., A. Bardelli, et. al. (2010). Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. The Journal of Clinical Investigation. 120: 2858-2866.
Moroney, J.W., R. Kurzrock, et. al. (2011). A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin. Cancer Res. 17: 6840-6846.
Janku, F., R. Kurzrock, et. al. (2011). "PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors." Molecular Cancer Therapeutics. 10: 558-65
mTOR Inhibitor sensitivity: PTEN loss
Di Nicolantonio, F., Arena, S., Tabernero, J., Grosso, S., Molinari, F., Macarulla, T., Russo, M., Cancelliere, C., Zecchin, D., Mazzucchelli, L., et al. (2010). Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 120: 2858-2866.
Moroney, J.W., Schlumbrecht, M.P., Helgason, T., Coleman, R.L., Moulder, S., Naing, A., Bodurka, D.C., Janku, F., Hong, D.S., and Kurzrock, R. (2011). A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. Clin Cancer Res 17: 6840-6846.
mTOR Inhibitor resistance: KRAS mutation
Tredan, O., Treilleux, I., Wang, Q., Gane, N., Pissaloux, D., Bonnin, N., Petit, T., Cretin, J., Bonichon-Lamichhane, N., Priou, F., et al. (2012). Predicting everolimus treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. Target Oncol. Dec 2012.
Di Nicolantonio, F., Arena, S., Tabernero, J., Grosso, S., Molinari, F., Macarulla, T., Russo, M., Cancelliere, C., Zecchin, D., Mazzucchelli, L., et al. (2010). Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus. J Clin Invest 120: 2858-2866.